UNSPSC 51263164: Levobetaxolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8MR4W4O06J, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, hydrochloride, (2s)- but more generally known as levobetaxolol hydrochloride, which bears US NIH Compound Identifier 60656. Most nations, for tariff and trade purposes, schedule levobetaxolol hydrochloride under HS 29221980.

As of Q4 2014, LEVOBETAXOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levobetaxolol hydrochloride bears US NLM identifiers UMLS ID C0876234 and NCI Concept Code C66007. SMILES: CC(C)NC[C@@H](COC1CCC(CC1)CCOCC2CC2)O.CL.

UNSPSC 51263164 Levobetaxolol hydrochloride is a Commodity code that nominally refers to a specific ophthalmic beta-blocker pharmaceutical, but recent state and local procurement activity under this code does not align with that product scope. Instead, the tagged opportunities reflect community health and pharmacy benefit programs unrelated to levobetaxolol—Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB, and the Texas Health and Human Services Commission issued an RFI for direct-to-manufacturer prescription program capabilities. The code shows minimal relevant recent activity, with no solicitations actually seeking levobetaxolol or related ophthalmic pharmaceuticals.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; vendors must include shipping and delivery costs and comply with drug-free workplace certification and E-Verify requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 as a preliminary market-intelligence solicitation regarding direct-to-manufacturer prescription programs, requesting vendor capabilities for negotiating contracts outside traditional pharmacy benefit manager and group purchasing organization channels. Geographic activity is limited to Florida and Texas within the recent record. The mismatch between the code's pharmaceutical scope and the actual opportunities tagged suggests either miscoding by the issuing bodies or that this code is not currently a reliable indicator of state and local levobetaxolol procurement. Firms targeting pharmaceutical procurement should monitor whether future opportunities are properly coded or track this code's activity separately to identify any shift toward actual ophthalmic pharmaceutical purchases.